Beo Therapeutics

Supplementation with live microbial strains is a novel approach to modulate the synergy between the microbiome and the gastrointestinal system to treat hyperuricemia. A large proportion of the population in the Western world suffers from elevated serum uric acid levels, hyperuricemia. The condition is a causal risk factor for serious diseases such as gout, hypertension, chronic kidney disease and type 2 diabetes.  Current standard treatment for hyperuricemia only brings 50% of patients below the recommended treatment target leaving a significant unmet medical need for safe and efficacious treatments. The product will be developed by an innovative combination of a food-supplement development path with pharmaceutical drug development approaches. This accelerates development timelines significantly. The product may be developed for multiple applications as food-supplement, medical food or drug.

Website

http://www.beotherapeutics.com

Externer Link zu Beo Therapeutics

Branche

Arzneimittelherstellung

Größe

2–10 Beschäftigte

Hauptsitz

Zürich, Zürich

Art

Privatunternehmen

Gegründet

2019